Sutro Biopharma STRO Non Cash Interest Expense On Deferred Royalty Obligation
Non Cash Interest Expense On Deferred Royalty Obligation at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept stro:NonCashInterestExpenseOnDeferredRoyaltyObligation.
The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sutro Biopharma's non cash interest expense on deferred royalty obligation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sutro Biopharma's non cash interest expense on deferred royalty obligation?
- Sutro Biopharma (STRO) reported non cash interest expense on deferred royalty obligation of $9.47M in Q1 2026.
- How has Sutro Biopharma's non cash interest expense on deferred royalty obligation changed year-over-year?
- Sutro Biopharma's non cash interest expense on deferred royalty obligation increased by 1.3% year-over-year, from $9.34M to $9.47M.
- What does non cash interest expense on deferred royalty obligation mean?
- This reflects the non-cash interest expense accrued on obligations related to future royalty payments or similar financing arrangements. It represents the cost of capital associated with deferred liabilities that do not require current cash settlement. Investors track this to understand the underlying financial leverage and the impact of non-cash financing costs on reported earnings.